Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol

Alberto Bongiovanni, Chiara Liverani, Sara Pusceddu, Silvana Leo, Giovanni Di Meglio, Stefano Tamberi, Daniele Santini, Fabio Gelsomino, Francesca Pucci, Rossana Berardi, Ivan Lolli, Francesca Bergamo, Sergio Ricci, Flavia Foca, Stefano Severi, Toni Ibrahim, SENECA Study Team Investigators, Mauro Cives, Davide Campana, Nicola Silvestris, Angela Buonadonna, Giuseppe Badalamenti, Maria Pia Brizzi, Alfredo Berruti, Francesca Spada, Sara Cingarlini, Lorenzo Antonuzzo, Davide Pastorelli, Mauro Cives, Davide Campana, Nicola Silvestris, Angela Buonadonna, Giuseppe Badalamenti, Maria Pia Brizzi, Alfredo Berruti, Francesca Spada, Sara Cingarlini, Lorenzo Antonuzzo, Davide Pastorelli, Alberto Bongiovanni, Chiara Liverani, Sara Pusceddu, Silvana Leo, Giovanni Di Meglio, Stefano Tamberi, Daniele Santini, Fabio Gelsomino, Francesca Pucci, Rossana Berardi, Ivan Lolli, Francesca Bergamo, Sergio Ricci, Flavia Foca, Stefano Severi, Toni Ibrahim, SENECA Study Team Investigators, Mauro Cives, Davide Campana, Nicola Silvestris, Angela Buonadonna, Giuseppe Badalamenti, Maria Pia Brizzi, Alfredo Berruti, Francesca Spada, Sara Cingarlini, Lorenzo Antonuzzo, Davide Pastorelli, Mauro Cives, Davide Campana, Nicola Silvestris, Angela Buonadonna, Giuseppe Badalamenti, Maria Pia Brizzi, Alfredo Berruti, Francesca Spada, Sara Cingarlini, Lorenzo Antonuzzo, Davide Pastorelli

Abstract

Introduction: Patients with metastatic or locally advanced, non-resectable, grade 3 poorly differentiated gastroenteropancreatic (GEP) and lung neuroendocrine carcinomas (NECs) are usually treated with in first-line platinum compounds. There is no standard second-line treatment on progression. Accurate biomarkers are needed to facilitate diagnosis and prognostic assessment of patients with NEC.

Methods and analysis: The SEcond-line therapy in NEuroendocrine CArcinomas (SENECA) study is a randomised, non-comparative, multicentre phase II trial designed to evaluate the efficacy and safety of folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) or capecitabine plus temozolomide (CAPTEM) regimens after failure of first-line chemotherapy in patients with lung NEC and GEP-NEC. Secondary aims are to correlate the serum miRNA profile and primary mutational status of MEN1, DAXX, ATRX and RB-1 with prognosis and outcome and to investigate the prognostic and predictive role of the Ki-67 score and 18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) or 68Ga-PET/CT. The main eligibility criteria are age ≥18 years; metastatic or locally advanced, non-resectable, grade 3 lung or GEP-NECs; progression to first-line platinum-based chemotherapy. A Bryant and Day design taking into account treatment activity and toxicity was used to estimate the sample size. All analyses will be performed separately for each treatment group in the intention-to-treat population. A total of 112 patients (56/arm) will be randomly assigned (1:1) to receive FOLFIRI every 14 days or CAPTEM every 28 days until disease progression or unacceptable toxicity or for a maximum of 6 months. Patients undergo testing for specific biomarkers in primary tumour tissue and for miRNA in blood samples. MiRNA profiling will be performed in the first 20 patients who agree to participate in the biological substudy.

Ethics and dissemination: The SENECA trial, supported by Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), was authorised by the locals Ethics Committee and the Italian Medicines Agency (AIFA). Results will be widely disseminated via peer-reviewed manuscripts, conference presentations and reports to relevant authorities.The study is currently open in Italy.

Trail registration number: NCT03387592; Pre-results. EudraCT-2016-000767-17.

Protocol version: Clinical Study Protocol Version 1, 7 November 2016.

Keywords: CAPTEM; FOLFIRI; capecitabine, temozolomide; neuroendocrine carcinoma; second-line.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
SEcond-line therapy in NEuroendocrine CArcinomas (SENECA) study design. CAPTEM, capecitabine plus temozolomide; FOLFIRI, folinic acid, 5-fluorouracil and irinotecan; GEP, gastroenteropancreatic.

References

    1. Kulke MH, Shah MH, Benson AB, et al. . Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw 2015;13:78–108. 10.6004/jnccn.2015.0011
    1. Modlin IM, Moss SF, Chung DC, et al. . Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 2008;100:1282–9. 10.1093/jnci/djn275
    1. Yao JC, Hassan M, Phan A, et al. . One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. JCO 2008;26:3063–72. 10.1200/JCO.2007.15.4377
    1. Fraenkel M, Kim M, Faggiano A, et al. . Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer 2014;21:R153–63. 10.1530/ERC-13-0125
    1. Lloyd RV, Osamura RY, Klöppel G, et al. . WHO classification of tumours of endocrine organs. 4th edn Lyon: International Agency for Research on Cancer (IARC), 2017.
    1. Sorbye H, Welin S, Langer SW, et al. . Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013;24:152–60. 10.1093/annonc/mds276
    1. Heetfeld M, Chougnet CN, Olsen IH, et al. . Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2015;22:657–64. 10.1530/ERC-15-0119
    1. Walter T, Malka D, Hentic O, et al. . Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: the PRODIGE 41-BEVANEC randomized phase II study. Dig Liver Dis 2018;50:195–8. 10.1016/j.dld.2017.11.020
    1. Hadoux J, Malka D, Planchard D, et al. . Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer 2015;22:289–98. 10.1530/ERC-15-0075
    1. Olsen IH, Sørensen JB, Federspiel B, et al. . Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. Sci World J (2012) 2012;2012:1–4. 10.1100/2012/170496
    1. Hentic O, Hammel P, Couvelard A, et al. . FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer 2012;19:751–7. 10.1530/ERC-12-0002
    1. Welin S, Sorbye H, Sebjornsen S, et al. . Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011;117:4617–22. 10.1002/cncr.26124
    1. Noda K, Nishiwaki Y, Kawahara M, et al. . Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85–91. 10.1056/NEJMoa003034
    1. Derks JL, Leblay N, Thunnissen E, et al. . Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res 2018;24:33–42. 10.1158/1078-0432.CCR-17-1921
    1. Tang LH, Untch BR, Reidy DL, et al. . Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res 2016;22:1011–7. 10.1158/1078-0432.CCR-15-0548
    1. Liverani C, Bongiovanni A, Mercatali L, et al. . Grading of neuroendocrine carcinomas: correlation of 68Ga-PET/CT scan with tissue biomarkers. Dis Markers 2018;2018:1–8. 10.1155/2018/6878409
    1. Grolmusz VK, Kövesdi A, Borks K, et al. . Prognostic relevance of proliferation-related miRNAs in pancreatic neuroendocrine neoplasms. Eur J Endocrinol 2018;179:219–28. 10.1530/EJE-18-0305
    1. Gill P, Kim E, Chua TC, et al. . MiRNA-3653 is a potential tissue biomarker for increased metastatic risk in pancreatic neuroendocrine tumours. Endocr Pathol 2019;30:128–33. 10.1007/s12022-019-9570-y
    1. Panarelli N, Tyryshkin K, Wong JJM, et al. . Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing. Endocr Relat Cancer 2019;26:47–57. 10.1530/ERC-18-0244
    1. Malczewska A, Kidd M, Matar S, et al. . A comprehensive assessment of the role of miRNAs as biomarkers in gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology 2018;107:73–90. 10.1159/000487326
    1. Bongiovanni A, Riva N, Ricci M, et al. . First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma. Onco Targets Ther 2015;8:3613–9. 10.2147/OTT.S91971
    1. Sansovini M, Severi S, Ianniello A, et al. . Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE. Eur J Nucl Med Mol Imaging 2017;44:490–9. 10.1007/s00259-016-3533-z
    1. Perren A, Couvelard A, Scoazec J-Y, et al. . ENETS consensus guidelines for the Standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology 2017;105:196–200. 10.1159/000457956
    1. Sorbye H, Köhne C-H, Sargent DJ, et al. . Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol 2007;18:1666–72. 10.1093/annonc/mdm267
    1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81. 10.1080/01621459.1958.10501452
    1. Strosberg JR, Fine RL, Choi J, et al. . First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268–75. 10.1002/cncr.25425

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi